18.10.2011 • News • Job Cuts • pharma industry • patent cliff

AstraZeneca to Cut 400 U.S. Jobs

AstraZeneca has announced plans to cut about 400 employees in its U.S. commercial operations, citing a need to reduce costs. The company said the jobs are mainly at its U.S. headquarters in Wilmington, Del., and some field-based, non-sales roles. The company has about 14,400 employees in North America. About 70 of the estimated positions to be eliminated will come from existing vacancies, leaving about 330 current workers affected by the cuts, said spokesman Tony Jewell. The specific jobs targeted haven't been identified yet. All decisions will be finalized by early December.

"The changes will enable the company to compete in a challenging environment, including pricing pressures and the continuing growth of generics medicines," the company said in a press release.

Several of AstraZeneca's best-selling drugs face the loss of patent expiration in coming years.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.